Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA(1c)

Diabetes Care

Volumn 23, Issue 9, 2000, Pages 1236-1241

  Bastyr III, E J ^a   Stuart, C A ^a   Brodows, R G ^a   Schwartz, S ^a   Graf, C J ^a   Zagar, A ^a   Robertson, K E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SUSTACAL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0033850956     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.9.1236     Document Type: Article

References (30)

1. Oral agent therapy in the treatment of type 2 diabetes
2. Optimizing blood glucose control in type 2 diabetes: An approach based on fasting blood glucose measurements
3. A comparison of the predictive power for overall blood glucose control of a 'good' fasting level in type 2 diabetic patients on diet alone or with oral agents
4. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy
5. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations in diagnostic methods for diabetes
6. Comparison of fasting and 2-hour glucose and HbA(1c) levels for diagnosing diabetes: Diagnostic criteria and performance revisited
7. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: The chicago heart association detection project in industry study
8. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu heart program
9. Risk factors for myocardial infarction and death in newly detected NIDDM: The diabetes intervention study, 11-year follow-up
10. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall study, the Paris prospective study, and the Helsinki policemen study
11. Classification and diagnosis of diabetes mellitus and impaired glucose tolerance
12. Standards of medical care for patients with diabetes mellitus (Position Statement)
13. Diabetes treatment satisfaction questionnaire (DTSQ)
14. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
15. Comparison of combined therapies in treatment of secondary failure to glyburide
16. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy: Results of a prospective randomized study in 50 patients
17. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment
18. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects
19. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes
20. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
22. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter randomized placebo-controlled clinical trials
23. Glimepiride, a new once-daily sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
24. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
25. Standards of medical care for patients with diabetes mellitus (Position Statement)
26. Glycosylated hemoglobin in normal subjects and subjects with maturity-onset diabetes: Evidence for a saturable system in man
27. Is HbA(1c) measurement superfluous in NIDDM?
28. Rational for prevention and treatment of postprandial glucose-mediated toxicity
29. The relationship of glycemic exposure (HbA(1c)) to the risk of development and progression of retinopathy in the diabetes control and complications trial
30. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control